European Biotechnology Magazine

Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain

German drugmaker Boehringer Ingelheim and Denmark’s Zealand Pharma have reported positive Phase 3 results for their experimental obesity drug survodutide, which met its primary cardiovascular safety … more ➔

fundraising

Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic

London-based Kesmalea Therapeutics has raised $60 million (about €53.5 million) in a Series A-2 financing and rebranded as Oyster Therapeutics. The funding will support the development of an oral, … more ➔

Credit: Danielle-Claude Bélanger via Unsplash+

heart disease

Novo, Novartis drugs cut heart-risk markers but not cardiovascular events

Danish drugmaker Novo Nordisk’s anti-inflammatory antibody ziltivekimab and Swiss drugmaker Novartis’ lipoprotein(a)-lowering drug pelacarsen sharply reduced their targeted blood markers but failed to … more ➔

Meanwhile in biotech

Windward targets $204M IPO; Valneva’s Shigella vaccine meets Phase 2 endpoint; Ethris’ nasal mRNA lowers viral load

A Swiss biotech moves closer to Nasdaq, while Valneva and Ethris report mid-stage clinical results. This week’s roundup also covers a takeover offer for Egetis, Sanofi’s latest pipeline cut and Vivoryon’s … more ➔

startup

Neobe raises $6.8M to break tumor barriers with bacteria

British biotech Neobe Therapeutics has raised $6.8 million (€6.1 million) in seed funding to develop engineered bacteria that break down the physical barriers preventing cancer drugs and immune cells … more ➔

European Biotechnology

1 / 4

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo

2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo

3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo

4 / 4

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.

Subscribe to our free newsletter!Subscribe here

uveal melanoma

Immunocore doubles up on T-cell engagers in eye cancer

U.K. biotech Immunocore has reported an estimated 70% two-year survival rate among 17 evaluable first-line metastatic uveal melanoma patients given its experimental drug brenetafusp alongside approved … more ➔

M&A

argenx buys macrocycle partner Unnatural Products for up to $1.15 billion

Dutch-Belgian immunology company argenx has agreed to acquire California-based Unnatural Products Inc. (UNP) for up to $1.15 billion (€1.03 billion), turning an existing drug-discovery partnership … more ➔

APPOINTMENTS

all appointments

Spica Therapeutics

Oculis taps Roche veteran after setback; ARTHEx brings in Azafaros’ CMO; CRISPR recruits Orna’s former CTO

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: neuroscience experience for Oculis, … more ➔

All news

EVENT

ICPO

November 12 - November 13

How Will Theranostics Shape Patient Care Within 5 Years?

The ICPO Summit 2026 will present the latest breakthroughs in Theranostics during impactful talks and interactive panel discussions featuring over 30 renowned international experts to learn how to expand global patient access to Theranostics. Look forward to fresh inspiration for your clinical practice! ➔

Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain

Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic

Novo, Novartis drugs cut heart-risk markers but not cardiovascular events

Windward targets $204M IPO; Valneva’s Shigella vaccine meets Phase 2 endpoint; Ethris’ nasal mRNA lowers viral load

Neobe raises $6.8M to break tumor barriers with bacteria

European Biotechnology

NEWSLETTER

Stay up to date with the biotech industry!

Immunocore doubles up on T-cell engagers in eye cancer

argenx buys macrocycle partner Unnatural Products for up to $1.15 billion

Sponsored Publications

CDMO: How to find a reliable partner

The CDMO partner for next-gen medicine

APPOINTMENTS

New CEO for the next level

New CEO took over the reins

Samanta Cimitan to (re)join Lonza from Celonic

Clinical Development Expert has started

When genetic medicine enters the inner ear

Spinal muscular atrophy: Tumors reported following Novartis gene therapy

Oculis taps Roche veteran after setback; ARTHEx brings in Azafaros’ CMO; CRISPR recruits Orna’s former CTO

EVENT

How Will Theranostics Shape Patient Care Within 5 Years?

Stay up to date every week with the european biotechnology newsletter.

Stay up to date every week with the european biotechnology newsletter.

European Biotechnology

NEWSLETTER

Stay up to date with the biotech industry!

Sponsored Publications

EVENT

How Will Theranostics Shape Patient Care Within 5 Years?